Literature DB >> 21481974

[Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].

J L Guinot1, J V Ricós, J Gimeno, M I Tortajada, M Carrascosa, M Santos, J Casanova, P Soler, V Crispín, L Arribas.   

Abstract

INTRODUCTION: We review the experience with prostate carcinoma patients treated with permanent implants of 125-I seeds and the outcome eight years after the beginning of this technique.
MATERIAL AND METHODS: From 2002 to 2007 we have performed 250 implants with LDR brachytherapy with RapidStrand(®) and preplanning system. Mean age was 68 (49-78). Mean PSA was 7.32 (2.31 - 14.6). T1-T2a was the stage in 98%, and Gleason ≤ 6 in 96%. Low risk cases were 81% and intermediate risk 19% (ten of them received 46 Gy EBRT). Hormonal treatment was used in 42%.
RESULTS: With a mean follow-up of 48 months, 14 patients (5.7%) showed biochemical failure (BF). Eleven patients (4.5%) with theoretical BF were observed and PSA decreased without treatment. Actuarial PSA relapse-free survival at 5 years was 91%, (92% low risk, 86% intermediate cases), and 92% vs 81% with PSA <10 vs >10 (p<0.05). Rectum complications were G2 in 0.6%. A urinary catheter was necessary in 6.5%. Sexual function was conserved in 60%. Mean V100 was 89% and D90 143 Gy.
CONCLUSION: The outcome of patients with low risk prostate carcinoma treated with I-125 seed is very good with very low complications rate. Cases with PSA bounces should be controlled before starting a salvage treatment.
Copyright © 2010 AEU. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481974     DOI: 10.1016/j.acuro.2011.02.003

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  1 in total

1.  Comparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer.

Authors:  Jose Luis Guinot; Jose Vicente Ricós; Maria Isabel Tortajada; Miguel Angel Santos; Juan Casanova; Jose Clemente; Josefa Samper; Paula Santamaría; Leoncio Arribas
Journal:  J Contemp Brachytherapy       Date:  2015-08-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.